By Jon Peterson2021-05-18T14:33:00+01:00
Meridiam is seeking to raise €1.8bn for its latest European infrastructure fund, according to an investor’s meeting document.
Sacramento County Employees’ Retirement System (SCERS) revealed it approved a €42m commitment to the Meridiam Sustainable Infrastructure Europe IV fund last month.
According to fund raising sources, the fundraising by Meridiam is at its early stages.
It is also understood that Maine Public Employees Retirement System has recently made an €85m commitment to the core-plus fund which targets a variety of infratsture assets.
Meridiam raised €1.3bn for the predecessor Meridiam Sustainable Infrastructure Europe III fund in April 2016.
San Francisco keeps Callan as deferred compensation plan consultant
San Francisco keeps Callan as deferred compensation plan consultant
Callan as investment consultant of its $4.1 billion 457 plan.
The system issued an RFP in October due to the upcoming expiration of Callan s contract on June 30, 2021.
The system s board approved a new five-year contract for Callan beginning July 1 at its meeting Wednesday, said spokesman Stephen Worsfold.
Related Articles
E-MAIL NEWSLETTERS Sign up and get the best of News delivered straight to your email inbox, free of charge. Choose your news – we will deliver.
Email Address
Subscribe Today Get access to the news, research and analysis of events affecting the retirement and institutional money management businesses from a worldwide network of reporters and editors. Subscribe
ADVERTISEMENT
ADVERTISEMENT
Funds Rip Ghosn s Appeal Bid In Nissan Pay Scandal Suit
Law360 (February 5, 2021, 9:18 PM EST) Two pension funds said Thursday that Nissan s fugitive ex-chairman Carlos Ghosn must face claims in Tennessee federal court alleging his purported financial misdeeds triggered investors losses and that he shouldn t be allowed to pursue an immediate appeal in a bid to escape jurisdiction.
Jackson County Employees Retirement System and Providence Employees Retirement System filed a brief opposing Ghosn s request for an interlocutory appeal of U.S. District Judge William L. Campbell Jr. s Dec. 29 decision declining to toss claims against Ghosn on personal jurisdiction grounds. Judge Campbell had also kept alive claims against Japanese automaker Nissan Motor Co. Ltd. and several other.
San Francisco Employees allocates $148 million to 3 alts funds
Print
San Francisco City & County Employees Retirement System disclosed commitments and investments totaling $148 million in a report from CIO William J. Coaker Jr. ahead of its Feb. 10 board meeting.
The $30.7 billion pension fund made a direct hedge fund investment of $100 million in
RTW Innovation Fund, an opportunistic fund that invests in health-care companies managed by RTW Investments.
It is SFERS first investment with RTW and is classified as an opportunistic investment within the pension fund s public equities portfolio.
As of Jan. 31, the actual allocation to public equities was 39.4%.
Also, SFERS committed $32 million to multistage venture capital fund LAV Fund VI and $16 million to late-stage venture capital fund LAV Fund VI Opportunities, both managed by
Class-Action Complaint Alleges AstraZeneca Misrepresented Promise of Vaccine
January 29, 2021 On Tuesday in the Southern District of New York, a class-action complaint was filed against AstraZeneca PLC and three company officials, claiming that the defendants violated the Securities Exchange Act of 1934 through an alleged fraudulent scheme that misrepresented AstraZeneca’s COVID-19 vaccine trials, inflated the company’s share prices, and deceived share purchasers.
Monroe County Employees’ Retirement System (MCERS) filed the complaint against AstraZeneca, a biopharmaceutical company, and Pascal Soriot, AstraZeneca CEO; Marc Dunoyer, chief financial officer and a director; and Menelas Pangalos, executive vice president of biopharmaceuticals research and development. The complaint was made on behalf of MCERS and all others who bought American depositary shares (ADS) of AstraZeneca starting May 21, 2020, through Nov. 20, 2020, known as the class period. AstraZeneca has ADSs tra